Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2,4-dihydroxyphenyl)-phenylmethanone
remaining 17beta HSD3 activity: 1.1%
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
-
12-acetyl-11,12-dihydro-2-(trifluoromethyl)-6H-dibenzo(b,f)(1,4)thiazocine
-
12-acetyl-11,12-dihydro-6H-dibenzo(b,f)(1,4)thiazocine
-
2,2',4,4'-tetrahydroxybenzophenone
remaining 17beta HSD3 activity: 47%
2,5-dioxo-3-(2-propyn-1-yl)-3-pyrrolidinecarboxylic acid 2,3,3-triphenyl-2-propen-1-yl-ester
-
2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-benzamide
-
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo(b,f)azocin-8-yl)-benzoic acid methyl ester
-
3-benzylidene camphor
remaining 17beta HSD3 activity: 56%
3alpha-butyl-3-hydroxy-5alpha-androstan-17-one
-
4-methylbenzylidene camphor
remaining 17beta HSD3 activity: 33%
5-acetyl-2-chloro-5,6-dihydro-dibenzo(b,f)azocine
-
5-acetyl-5,6,11,12-tetrahydro-dibenzo(b,f)(1,4)diazocine
-
N-(((3,5)-3-hydroxy-17-oxoandrostan-3-yl)methyl)-N-(tricyclo(3.3.1.13.7)dec-2-ylmethyl)butanamide
-
(3a,5a)-3-[[(2R,5S)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl]-2,5-dimethylpiperazin-1-yl]methyl]-17-methylideneandrostan-3-ol
-
-
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
-
i.e. RM-532-105
(4-(2,4-dichlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(2-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(2-methoxyphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(3-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-bromophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chloro-2-(hydroxymethyl)phenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chloro-2-methylphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorobenzoyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorobenzyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorophenyl)-1,4-diazepan-1-yl)(morpholino)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(1-oxido-4-thiomorpholino)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(4-methylpiperazin-1-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(cyclohexyl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(morpholino)methanethione
-
(4-(4-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(phenyl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(piperidin-1-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(pyridin-4-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(tetrahydro-2H-pyran-4-yl)methanone
-
(4-(4-chlorophenyl)piperazin-1-yl)(thiomorpholino)methanone
-
(4-(4-ethynylphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-fluorophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-iodophenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(4-methoxyphenyl)piperazin-1-yl)(morpholino)methanone
-
(4-(6-bromopyridin-2-yl)piperazin-1-yl)(morpholino)methanone
-
(4-(6-chloropyridin-3-yl)piperazin-1-yl)(morpholino)methanone
-
(4-(biphenyl-4-yl)piperazin-1-yl)(morpholino)methanone
-
(5-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)(morpholino)methanone
-
1-(11,12-dihydro-6H-dibenzo[b,f]oxocin-12-yl)ethanone
-
IC50: 0.00297 mM
1-(4-(4-(4-chlorophenyl)piperazine-1-carbonyl)piperazin-1-yl)-2-hydroxyethanone
-
1-(4-(4-chlorophenyl)piperazine-1-carbonyl)piperidine-4-carboxylic acid
-
1-(5,6,11,12-tetrahydrodibenzo[b,f]azocin-12-yl)ethanone
-
IC50: 0.00474 mM
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]ethanone
-
IC50: 0.02 nM
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
11-[3-hydroxy-17-beta-hydroxyestr-5(10)-en-17alpha-yl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl]-undecanoic acid butyl-methyl-amide
-
selective inhibition of type 2 17beta-HSD
12-acetyl-1-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.0115 mM
12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocin-3-ol
-
IC50: 0.0049 mM
12-acetyl-2,3-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00001 mM
12-acetyl-2-(trifluoromethyl)-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00281 mM
12-acetyl-2-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00003 mM
12-acetyl-3,4-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00076 mM
12-acetyl-3-bromo-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00025 mM
12-acetyl-3-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00010 mM
12-acetyl-3-fluoro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00009 mM
12-acetyl-3-methoxy-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.0021 mM
12-acetyl-3-methyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.001 mM
17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM
17alpha-ethynyl-estradiol
17beta-dihydroequilin
-
0.01 mM, 88% inhibition, reaction with 0.002 mM estradiol
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 3 nM
2-hydroxy-estradiol
-
0.01 mM, 67% inhibition, reaction with 0.002 mM estradiol
20alpha-dihydroprogesterone
-
0.01 mM, 71% inhibition, reaction with 0.002 mM estradiol, inhibits oxidation of testosterone
3,4-dihydrobenzoic acid
-
0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione
3-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 3 nM
3-hydroxy-1,3,5(10)-estratriene-17beta-O,17alpha-butanolactone
-
selective for type 2 17beta-HSD versus types 1, 3, and 7 but not versus type 5 17beta-HSD
3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM
3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone
-
IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase
3alpha-alkylated androsterone derivatives
-
17-88% inhibition at 0.003 mM, overview
-
3alpha-ether-3beta-substituted androsterone derivatives
-
diverse derivatives, IC50: 70-760 nM, overview
-
3beta-alkylated androsterone derivatives
-
IC50: 57-147 nM
-
3beta-cyclohexylethyl-androsterone
-
-
3beta-hexyl-androsterone
-
-
3beta-phenyl-androsterone
-
mixed-type inhibition, shows some proliferative activity on AR+ and Er+ cell lines not mediated through androgen or estrogen receptors
3beta-phenylethyl-3alpha-methyl-O-androsterone
-
IC50: 73 nM
3beta-phenylethyl-androsterone
3beta-phenylmethyl-androsterone
3beta-substituted androsterone derivatives
-
IC50: 57-147 nM
-
4-((4-(4-chlorophenyl)piperazin-1-yl)sulfonyl)morpholine
-
4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzoic acid
-
4-(4-chlorophenyl)-N-cyclohexylpiperazine-1-carboxamide
-
4-(4-chlorophenyl)-N-phenylpiperazine-1-carboxamide
-
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)-N-methylbenzamide
-
IC50: 25 nM
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 5 nM
4-[4-(4-chlorophenyl)piperazine-1-carbonyl]-thiomorpholine-1,1-dione
-
5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00007 mM
5-acetyl-2-chloro-5,6-dihydrodibenzo[b,f]azocine
-
IC50: 0.00024 mM
5-acetyl-2-chloro-8-(2-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 3 nM
5-acetyl-2-chloro-8-(3-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 8 nM
5-acetyl-2-chloro-8-(4-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 2 nM
5-acetyl-2-chloro-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 4 nM
5-acetyl-3-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00005 mM
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
-
IC50: 0.00049 mM
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine-9-carboxamide
-
IC50: 0.001 mM
5-acetyl-8-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 9 nM
5-acetyl-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.02 nM
5-acetyl-9-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 7 nM
5-acetyl-N-cyclohexyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
-
IC50: 8 nM
5alpha-androstane-3alpha,17beta-diol
-
0.01 mM, 87% inhibition, reaction with 0.002 mM estradiol
5alpha-dihydrotestosterone
-
inhibits oxidation of testosterone
5beta-androstane-3alpha,17beta-diol
-
0.01 mM, 83% inhibition, reaction with 0.002 mM estradiol
5beta-dihydrotestosterone
-
inhibits oxidation of testosterone
9-bromo-11,12-dihydrodibenzo[b,f]azocine-5(6H)-carboxamide
-
IC50: 0.00028 mM
9-bromo-5-butanoyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00032 mM
9-bromo-5-ethyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.001 mM
9-cis-retinoic acid
-
weak
beta-octylglucoside
-
strong
chloromercuribenzene-p-sulfonic acid
-
-
danazol
-
inhibits oxidation of testosterone, 0.01 mM, 83% inhibition
dibenzothiazocine
-
IC50: 0.0004 mM
dodecyl-beta-D-maltoside
-
inhibition above 0.5%
EM-919
-
a 17beta-HSD type 2 inhibitor
estradiol
-
inhibits oxidation of testosterone
estrone
substrate inhibition
gallic acid
-
0.001 mM, 50% inhibition, reduction of androst-4-en-3,17-dione
GTx-560
competitively and selectively inhibits AKR1C3-dependent androgen receptor transactivation. GTx-560 completely blocks the formation of testosterone from androstenedione, indicating the ability of AKR1C3 inhibitors, unlike 5alpha-reductase inhibitors, to reduce testosterone levels
methyl 12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine-3-sulfinate
-
IC50: 0.01 mM
methyl 3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
-
IC50: 0.00004 mM
methyl 4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzoate
-
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
methyl [3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
-
IC50: 0.00014 mM
methyl [4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
-
IC50: 2 nM
morpholino(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)methanone
-
morpholino(4-(4-nitrophenyl)piperazin-1-yl)methanone
-
morpholino(4-(naphthalen-2-yl)piperazin-1-yl)methanone
-
morpholino(4-(o-tolyl)piperazin-1-yl)methanone
-
morpholino(4-(p-tolyl)piperazin-1-yl)methanone
-
morpholino(4-(quinolin-3-yl)piperazin-1-yl)methanone
-
morpholino(4-phenylpiperazin-1-yl)methanone
-
-
morpholino-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methanone
-
N,N-dimethyl-4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
N-(4-(4-(morpholine-4-carbonyl)piperazin-1-yl)phenyl)acetamide
-
N-(4-(4-(morpholine-4-carbonyl)piperazin-1-yl)phenyl)methanesulfonamide
-
N-(5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-yl)benzamide
-
IC50: 0.00016 mM
N-methyl-4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
oleuropein glycoside
-
0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione
p-chloromercuribenzoate
-
-
spiro-gamma-lactone-estradiol
-
inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM
spironolactone
-
IC50 for oxidation of testosterone: 0.0011 mM
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.212 mg/ml result in 50% enzyme inhibition
-
testosterone
-
0.01 mM, 70% inhibition, reaction with 0.002 mM estradiol
tetrahydrodibenzazocine
-
IC50: 0.00009 mM
Triton X-100
-
significant
[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanol
-
IC50: 0.9 nM
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
-
IC50: 0.00024 mM
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
-
IC50: 0.00029 mM
17alpha-ethynyl-estradiol
-
0.01 mM, 54% inhibition, reaction with 0.002 mM estradiol
17alpha-ethynyl-estradiol
-
inhibits oxidation of testosterone
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM
3beta-phenylethyl-androsterone
-
-
3beta-phenylethyl-androsterone
-
IC50: 99 nM
3beta-phenylmethyl-androsterone
-
IC50: 57 nM
3beta-phenylmethyl-androsterone
-
mixed-type inhibition, shows some proliferative activity on AR+ and Er+ cell lines not mediated through androgen or estrogen receptors
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
-
IC50: 0.00004 mM
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
-
IC50: 0.7 nM
additional information
-
design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-HSD, the bisubstrate inhibitors are less potent in intact cells than in homogenated cells, overview, the best inhibitors of that series are those bearing an alkyl side-chain spacer of 11 or 12 methylenes with inhibition of 69% and 78% at 1 mM
-
additional information
-
synthesis, inhibitory potency, and in vivo effects of the diverse inhibitor derivatives, detailed overview
-
additional information
high-throughput screening, a series of non-carboxylate morpholino(phenylpiperazin-1-yl)methanones are prepared by palladium-catalysed coupling of substituted phenyl or pyridyl bromides with morpholino(piperazin-1-yl)methanone, and are shown to be potent and very isoform-selective inhibitors of AKR1C3, competitive fluorescence assay, structure-activity relationships, overview
-
additional information
small-molecule inhibitors inhibit both the enzymatic and coactivator functions of AKR1C3 resulting in androgen-dependent prostate cancer and CRPC regression. No inhibition by indomethacin
-
additional information
-
small-molecule inhibitors inhibit both the enzymatic and coactivator functions of AKR1C3 resulting in androgen-dependent prostate cancer and CRPC regression. No inhibition by indomethacin
-
additional information
17beta-HSD1 and 17beta-HSD2 inhibitor structures and their biological activities are reviewed
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
17beta-estradiol 17-dehydrogenase deficiency
Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3).
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
"Any decision is better than none" decision-making about sex of rearing for siblings with 17beta-hydroxysteroid-dehydrogenase-3 deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17 alpha-hydroxylation deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17 beta-hydroxysteroid dehydrogenase 3 deficiency in the Mediterranean population.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17 beta-hydroxysteroid dehydrogenase deficiency in malignant interstitial cell carcinoma of the testis.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17 beta-hydroxysteroid dehydrogenase deficiency with minimal virilization and spontaneous reduction of serum androgens to normal female levels.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17beta-hydroxysteroid dehydrogenase type 3 deficiency as a result of a homozygous 7 base pair deletion in 17betaHSD3 gene.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
17beta-Hydroxysteroid dehydrogenase-3 deficiency: from pregnancy to adolescence.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
3 alpha-Androstanediol glucuronide in premature and normal pubarche.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency. Follow-up study in a girl with pubertal bone age.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
3beta-hydroxysteroid dehydrogenase/delta5-->4-isomerase activity associated with the human 17beta-hydroxysteroid dehydrogenase type 2 isoform.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
46,XY DSD with Female or Ambiguous External Genitalia at Birth due to Androgen Insensitivity Syndrome, 5alpha-Reductase-2 Deficiency, or 17beta-Hydroxysteroid Dehydrogenase Deficiency: A Review of Quality of Life Outcomes.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
A case of late-onset congenital adrenal hyperplasia due to partial 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
A novel missense mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene in a family with classical salt-wasting congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
A Novel Nonsense Mutation in HSD17B3 Gene in a Tunisian Patient with Sexual Ambiguity.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
A study of gender outcome of Egyptian patients with 46,XY disorder of sex development.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Anti-müllerian hormone in children with androgen insensitivity.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Characterization of two novel homozygous missense mutations involving codon 6 and 259 of type II 3beta-hydroxysteroid dehydrogenase (3betaHSD) gene causing, respectively, nonsalt-wasting and salt-wasting 3betaHSD deficiency disorder.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Clinical, endocrine, and molecular findings in 17beta-hydroxysteroid dehydrogenase type 3 deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Complexities of gender assignment in 17beta-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for early orchiectomy?
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Congenital adrenal hyperplasia in pregnancy.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Congenital adrenal hyperplasia in Turkey: a review of 273 patients.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Congenital adrenal hyperplasia owing to 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Congenital adrenal hyperplasia.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Defects in steroidogenic enzymes. Discrepancies between clinical steroid research and molecular biology results.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Detection of 3 beta-hydroxysteroid dehydrogenase deficiency in a newborn by means of urinary steroid analysis.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Dihydrotestosterone binding by cultured human fibroblasts. Comparison of cells from control subjects and from patients with hereditary male pseudohermaphroditism due to androgen resistance.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Familial male pseudohermaphroditism with gynaecomastia due to 17 beta-hydroxysteroid dehydrogenase deficiency. A report of 3 cases.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Genetic defects of steroidogenesis in premature pubarche.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Genetic diseases of steroid metabolism.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
High prevalence of abnormal adrenal response in girls with central precocious puberty at early pubertal stages.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Hirsutism due to late onset 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Human 3beta-hydroxysteroid dehydrogenase deficiency associated with normal spermatic numeration despite a severe enzyme deficit.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Hyperandrogenism due to 3 beta-hydroxysteroid dehydrogenase deficiency with accessory adrenocortical tissue: a hormonal and metabolic evaluation.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Hyperandrogenism in female adolescents.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Hypothalamic-pituitary-gonadal axis function in pubertal male and female siblings with glucocorticoid-treated nonsalt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Isolated precocious pubarche: an approach.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Late-onset 3 beta-hydroxysteroid dehydrogenase deficiency with virilization induced by a large ovarian cyst.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Male pseudohermaphroditism consistent with 17,20-desmolase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: gender reassignment in early infancy.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: studies on the natural history of the defect and effect of androgens on gender role.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Male pseudohermaphroditism due to 3 beta-hydroxysteroid dehydrogenase-isomerase deficiency associated with atrial septal defect.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: gender role change and absence of gynecomastia at puberty.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Masculinizing genitoplasty in intersex patients.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Mechanisms of androgen production in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency in children with accelerated growth, premature pubarche and/or hirsutism.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency with hyperaldosteronism.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Molecular analysis of type II 3 beta-hydroxysteroid dehydrogenase gene in Japanese patients with classical 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene in a patient with classic salt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Neutral 17beta-hydroxysteroid oxidoreductase deficiency in testes causing male pseudohermaphroditism in an infant.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Non-classical 3 beta-hydroxysteroid dehydrogenase deficiency in children in central Iowa. Difficulties in differentiating this entity from cases of precocious adrenarche without an adrenal enzyme defect.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency in young girls with hirsutism and premature pubarche.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency: a review of our experience with 25 female patients.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Normal ovarian function in a mild form of late-onset 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Pediatric disorders of sex development.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Plasma and urinary androgens and oestrogens in a pubertal boy with 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Possible testicular 3 beta-hydroxysteroid dehydrogenase deficiency in cryptorchid neonates.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Proceedings: 17beta-hydroxysteroid oxidoreductase deficiency causing male pseudohermaphroditism in a child.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Progressive virilization of a pubertal phenotypic female: 17 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Pubertal changes in testicular 3 beta-hydroxysteroid dehydrogenase activity in a male with classical 3 beta-hydroxysteroid dehydrogenase deficiency showing spontaneous secondary sexual maturation.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Regulation of Wolffian duct development.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Screening for mutations for 17 ?-hydroxysteroid dehydrogenase and androgen receptor in an adult female 46, XY DSD clinic.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Sigmoid reconfigured vaginal construction in children.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Steroid metabolism in testes of patients with incomplete masculinization due to androgen insensitivity or 17 beta-hydroxysteroid dehydrogenase deficiency and normally differentiated males.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Ten years experience with masculinizing genitoplasty in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
The Dilemma of Sex Reassignment in an Adolescent with 17beta-HSD-3 Deficiency Raised as a Female: Ten-Year Follow-Up.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
The incidence of late-onset congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency among hirsute women.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
The lack of HSD17B3 in male mice results in disturbed Leydig cell maturation and endocrine imbalance akin to humans with HSD17B3 deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
The response to human chorionic gonadotropin (HCG) administration in boys with and without delta5-3beta-hydroxysteroid dehydrogenase deficiency.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Treatment of clitoromegaly of culturally diverse patients.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Urinary 5-ene-steroid excretion in non-classical congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency (NC-3BHSD).
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Use of laparoscopy in intersex patients.
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[17 beta-hydroxysteroid dehydrogenase 3 deficiency due to novel compound heterozygous variants of HSD17B3 gene in a sib pair].
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[17 beta-Hydroxysteroid dehydrogenase deficiency]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[17beta-hydroxysteroid dehydrogenase deficiency]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[3 beta-hydroxysteroid dehydrogenase deficiency and 21-hydroxylase deficiency in hirsutism]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[3 beta-Hydroxysteroid dehydrogenase deficiency]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[Case report: congenital adrenal hyperplasia and ambiguous genitalia due to 3 beta-hydroxysteroid dehydrogenase deficiency]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[Dehydroepiandrosterone and dehydroepiandrosterone-sulfate content of the amniotic fluid]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[Partial 3-beta-hydroxysteroid dehydrogenase deficiencies]
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
[Severe 46,XY virilization deficit due to 17beta-hydroxysteroid dehydrogenase deficiency]
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Masculinizing genitoplasty in intersex patients.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Screening for mutations for 17 ?-hydroxysteroid dehydrogenase and androgen receptor in an adult female 46, XY DSD clinic.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Steroidogenesis of the testis -- new genes and pathways.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Androgens, androgen receptors, and male gender role behavior.
3alpha(17beta)-hydroxysteroid dehydrogenase (nad+) deficiency
Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency.
3beta-hydroxy-delta5-steroid dehydrogenase deficiency
The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.
3beta-hydroxysteroid 3-dehydrogenase deficiency
Masculinizing genitoplasty in intersex patients.
Abortion, Spontaneous
Evidence for association of the rs605059 polymorphism of HSD17B1 gene with recurrent spontaneous abortions.
Acne Vulgaris
Androgen metabolism in sebaceous glands from subjects with and without acne.
Acne Vulgaris
Association of HSD17B3 and HSD3B1 polymorphisms with acne vulgaris in Southwestern Han Chinese.
Acne Vulgaris
Cutaneous androgen metabolism: basic research and clinical perspectives.
Acne Vulgaris
Testosterone synthesized in cultured human SZ95 sebocytes derives mainly from dehydroepiandrosterone.
Acne Vulgaris
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
Addison Disease
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Adenocarcinoma
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in normal and carcinomatous endometrium.
Adenocarcinoma
Effect of gestagen therapy upon 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma.
Adenocarcinoma
Immunohistochemical study of the human 17 beta-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma.
Adenocarcinoma
Short-term effects of danazol and medroxyprogesterone acetate on cytosol and nuclear estrogen and progestin receptors, 17 beta-hydroxysteroid dehydrogenase activity, histopathology, and ultrastructure of human endometrial adenocarcinoma.
Adenocarcinoma
Steroid sulphotransferase and 17beta-hydroxysteroid dehydrogenase activities in Ishikawa human endometrial adenocarcinoma cells.
Adenocarcinoma
[Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)]
Adenoma
Acid phosphatases of dog testis and a Leydig cell tumor.
Adenoma
Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.
Adenoma
High expression of cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome associated with high secretion of adrenal androgens.
Adenoma
Increased 17 beta-hydroxysteroid dehydrogenase activity in a masculinizing adrenal adenoma in a patient with isolated testosterone overproduction.
Adenoma
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Adenoma
Primary aldosteronism associated with chronic renal failure. Report of a case.
Adenoma
Primary aldosteronism: treatment with trilostane.
Adenoma
Steroid biosynthesis in human adrenal tumors.
Adenomyosis
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Adenomyosis
[Temporal and spatial expression of estrogen activity-related molecules in eutopic endometrium of adenomyosis]
Adrenal Hyperplasia, Congenital
A case of late-onset congenital adrenal hyperplasia due to partial 3 beta-hydroxysteroid dehydrogenase deficiency.
Adrenal Hyperplasia, Congenital
A new compound heterozygous frameshift mutation in the type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene causes salt-wasting 3 beta-HSD deficiency congenital adrenal hyperplasia.
Adrenal Hyperplasia, Congenital
A novel missense mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene in a family with classical salt-wasting congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Adrenal Hyperplasia, Congenital
Absence of molecular defect in the type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene in premature pubarche children and hirsute female patients with moderately decreased adrenal 3 beta-HSD activity.
Adrenal Hyperplasia, Congenital
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
Adrenal Hyperplasia, Congenital
Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin.
Adrenal Hyperplasia, Congenital
Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Adrenal Hyperplasia, Congenital
Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase type II deficiency in 4 Saudi children. Long term follow up.
Adrenal Hyperplasia, Congenital
Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene.
Adrenal Hyperplasia, Congenital
Congenital adrenal hyperplasia in Turkey: a review of 273 patients.
Adrenal Hyperplasia, Congenital
Congenital adrenal hyperplasia owing to 3 beta-hydroxysteroid dehydrogenase deficiency.
Adrenal Hyperplasia, Congenital
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
Adrenal Hyperplasia, Congenital
Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia.
Adrenal Hyperplasia, Congenital
Human 3beta-hydroxysteroid dehydrogenase deficiency associated with normal spermatic numeration despite a severe enzyme deficit.
Adrenal Hyperplasia, Congenital
Hypothalamic-pituitary-gonadal axis function in pubertal male and female siblings with glucocorticoid-treated nonsalt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
Adrenal Hyperplasia, Congenital
Hypothalamic-pituitary-gonadal function in two infants with Smith-Lemli-Opitz syndrome.
Adrenal Hyperplasia, Congenital
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
Adrenal Hyperplasia, Congenital
Late onset adrenal hyperplasia due to 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency in north Indian hirsute women.
Adrenal Hyperplasia, Congenital
Male pseudohermaphroditism caused by nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency.
Adrenal Hyperplasia, Congenital
Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Adrenal Hyperplasia, Congenital
Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency.
Adrenal Hyperplasia, Congenital
Molecular genetics of congenital adrenal hyperplasia.
Adrenal Hyperplasia, Congenital
Mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene in a patient with classic salt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
Adrenal Hyperplasia, Congenital
Nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function.
Adrenal Hyperplasia, Congenital
Persistent testicular delta5-isomerase-3beta-hydroxysteroid dehydrogenase (delta5-3beta-HSD) deficiency in the delta5-3beta-HSD form of congenital adrenal hyperplasia.
Adrenal Hyperplasia, Congenital
Prevention of Mammary gland defects in experimental congenital adrenal hyperplasia due to inhibition to 3 beta-hydroxysteroid dehydrogenase in rats.
Adrenal Hyperplasia, Congenital
Sigmoid reconfigured vaginal construction in children.
Adrenal Hyperplasia, Congenital
Studies of 3 beta-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated delta 5-steroid levels.
Adrenal Hyperplasia, Congenital
The incidence of late-onset congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency among hirsute women.
Adrenal Hyperplasia, Congenital
Urinary 5-ene-steroid excretion in non-classical congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency (NC-3BHSD).
Adrenal Hyperplasia, Congenital
[Case report: congenital adrenal hyperplasia and ambiguous genitalia due to 3 beta-hydroxysteroid dehydrogenase deficiency]
Adrenal Hyperplasia, Congenital
[Dehydroepiandrosterone and dehydroepiandrosterone-sulfate content of the amniotic fluid]
Adrenocortical Adenoma
Enzyme histo-cytochemical studies in human adrenocortical adenomas. [II] Cushing's syndrome.
Adrenocortical Adenoma
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Adrenocortical Adenoma
Small adrenocortical tumors without apparent clinical endocrine abnormalities. Immunolocalization of steroidogenic enzymes.
Adrenocortical Carcinoma
Decrease in the expression of the 3beta-hydroxysteroid dehydrogenase gene in human adrenal tissue during prepuberty and early puberty: implications for the mechanism of adrenarche.
Adrenocortical Carcinoma
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Adrenogenital Syndrome
The adrenogenital syndrome with deficiency of 3 beta-hydroxysteroid dehydrogenase.
Adrenogenital Syndrome
[Unusual adrenogenital syndrome. Probable blockade of 3 beta-hydroxysteroid dehydrogenase in a 4-year-old boy]
Alzheimer Disease
Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model.
Alzheimer Disease
Aging and Lateralization of the Rat Brain on a Biochemical Level.
Alzheimer Disease
Polymorphisms in HSD17B1: Early Onset and Increased Risk of Alzheimer's Disease in Women with Down Syndrome.
Androgen-Insensitivity Syndrome
17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal.
Androgen-Insensitivity Syndrome
46,XY DSD with Female or Ambiguous External Genitalia at Birth due to Androgen Insensitivity Syndrome, 5alpha-Reductase-2 Deficiency, or 17beta-Hydroxysteroid Dehydrogenase Deficiency: A Review of Quality of Life Outcomes.
Androgen-Insensitivity Syndrome
Anti-müllerian hormone in children with androgen insensitivity.
Androgen-Insensitivity Syndrome
Masculinizing genitoplasty in intersex patients.
Androgen-Insensitivity Syndrome
Practical approach to steroid 5alpha-reductase type 2 deficiency.
Androgen-Insensitivity Syndrome
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Androgen-Insensitivity Syndrome
Regulation of Wolffian duct development.
Androgen-Insensitivity Syndrome
Use of laparoscopy in intersex patients.
aromatase deficiency
Ovarian steroidogenesis in Japanese patients with polycystic ovary syndrome.
Autoimmune Diseases
Human leukocyte antigen-DQB1* genotypes encoding aspartate at position 57 are associated with 3beta-hydroxysteroid dehydrogenase autoimmunity in premature ovarian failure.
Autoimmune Diseases
Identification of 3 beta-hydroxysteroid dehydrogenase as a novel target of steroid cell autoantibodies: association of autoantibodies with endocrine autoimmune disease.
Bladder Exstrophy
Sigmoid reconfigured vaginal construction in children.
Blindness
Retinol dehydrogenases RDH11 and RDH12 in the mouse retina: expression levels during development and regulation by oxidative stress.
Breast Diseases
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.
Breast Neoplasms
1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase.
Breast Neoplasms
17 beta-estradiol dehydrogenase (E2DH) activity in T47D cells.
Breast Neoplasms
17 Beta-hydroxysteroid dehydrogenase and aromatase activity in breast fat from women with benign and malignant breast tumours.
Breast Neoplasms
17 beta-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin.
Breast Neoplasms
17 Beta-hydroxysteroid dehydrogenase in human breast cancer: analysis of kinetic and clinical parameters.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
Breast Neoplasms
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
Breast Neoplasms
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Breast Neoplasms
17beta-hydroxysteroid dehydrogenases in human breast cancer.
Breast Neoplasms
17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer.
Breast Neoplasms
A comparison of the in vivo uptake and metabolism of 3H-oestrone and 3H-oestradiol by normal breast and breast tumour tissues in post-menopausal women.
Breast Neoplasms
A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro.
Breast Neoplasms
Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Breast Neoplasms
Active site analysis of 17beta-hydroxysteroid dehydrogenase type 1 enzyme complexes with SPROUT.
Breast Neoplasms
Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8.
Breast Neoplasms
Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism.
Breast Neoplasms
African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.
Breast Neoplasms
Amplification of HSD17B1 and ERBB2 in primary breast cancer.
Breast Neoplasms
Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer.
Breast Neoplasms
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Breast Neoplasms
Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Breast Neoplasms
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Breast Neoplasms
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Breast Neoplasms
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women.
Breast Neoplasms
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Breast Neoplasms
Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates.
Breast Neoplasms
Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Breast Neoplasms
Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue.
Breast Neoplasms
Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues.
Breast Neoplasms
Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Breast Neoplasms
Design, Synthesis, and Biological Evaluation of (Hydroxyphenyl)naphthalene and -quinoline Derivatives: Potent and Selective Nonsteroidal Inhibitors of 17beta-Hydroxysteroid Dehydrogenase Type 1 (17beta-HSD1) for the Treatment of Estrogen-Dependent Diseases.
Breast Neoplasms
Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Breast Neoplasms
Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells.
Breast Neoplasms
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
Breast Neoplasms
Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Breast Neoplasms
Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Breast Neoplasms
Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Breast Neoplasms
Effect of nomegestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells.
Breast Neoplasms
Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells.
Breast Neoplasms
Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells.
Breast Neoplasms
Estradiol 17 beta-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency.
Breast Neoplasms
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Breast Neoplasms
Estradiol as an anti-aromatase agent in human breast cancer cells.
Breast Neoplasms
Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Breast Neoplasms
Estrogen biosynthesis in breast adipose tissue during menstrual cycle in women with and without breast cancer.
Breast Neoplasms
Estrogen-related genes and their contribution to racial differences in breast cancer risk.
Breast Neoplasms
Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Breast Neoplasms
Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures.
Breast Neoplasms
Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence.
Breast Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.
Breast Neoplasms
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression.
Breast Neoplasms
Focused Libraries of 16-Substituted Estrone Derivatives and Modified E-Ring Steroids: Inhibitors of 17ss-Hydroxysteroid Dehydrogenase Type 1.
Breast Neoplasms
Genetic susceptibility to cancer from exogenous and endogenous exposures.
Breast Neoplasms
Genomic data on breast cancer transcript profile modulation by 17beta-hydroxysteroid dehydrogenase type 1 and 17-beta-estradiol.
Breast Neoplasms
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies.
Breast Neoplasms
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Breast Neoplasms
HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore.
Breast Neoplasms
HSD17B1 gene polymorphisms and risk of endometrial and breast cancer.
Breast Neoplasms
HSD17B1 Genetic Variants and Hormone Receptor-Defined Breast Cancer.
Breast Neoplasms
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.
Breast Neoplasms
Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts.
Breast Neoplasms
Human mammary cancer as a site of sex steroid metabolism.
Breast Neoplasms
Identification of albumin in breast tumor cytosol as a factor involved in the stimulation of estradiol 17 beta-hydroxysteroid dehydrogenase (reductive) activity.
Breast Neoplasms
Importance of estrogen sulfates in breast cancer.
Breast Neoplasms
In situ production of estrogens in human breast carcinoma.
Breast Neoplasms
In situ production of sex steroids in human breast carcinoma.
Breast Neoplasms
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Breast Neoplasms
Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Breast Neoplasms
Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells.
Breast Neoplasms
Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antiestrogens.
Breast Neoplasms
Insights in 17beta-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation.
Breast Neoplasms
Interactive effects of interleukin-6, 17 beta-estradiol and progesterone on growth and 17 beta-hydroxysteroid dehydrogenase activity in human breast carcinoma cells.
Breast Neoplasms
Interleukin-3: a putative protective factor against breast cancer which is secreted by male but not female breast fibroblasts.
Breast Neoplasms
Intracrine mechanism of estrogen synthesis in breast cancer.
Breast Neoplasms
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
Breast Neoplasms
Kinetic studies of oestradiol 17 beta-hydroxysteroid dehydrogenase in MCF-7 mammary cancer cells.
Breast Neoplasms
Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17beta-hydroxysteroid dehydrogenase type 1.
Breast Neoplasms
New development in intracrinology of breast carcinoma.
Breast Neoplasms
New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase.
Breast Neoplasms
Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. Effect on sulfatase activity in comparison to medroxyprogesterone acetate.
Breast Neoplasms
Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells.
Breast Neoplasms
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.
Breast Neoplasms
Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.
Breast Neoplasms
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Breast Neoplasms
Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer.
Breast Neoplasms
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Breast Neoplasms
Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Breast Neoplasms
Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells.
Breast Neoplasms
Regulation of 17 beta-hydroxysteroid dehydrogenase in a newly-established human breast carcinoma cell line.
Breast Neoplasms
Regulation of estradiol 17 beta-hydroxysteroid dehydrogenase expression and activity by retinoic acid in T47D breast cancer cells.
Breast Neoplasms
Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells.
Breast Neoplasms
Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer.
Breast Neoplasms
Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer.
Breast Neoplasms
Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Breast Neoplasms
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Breast Neoplasms
Role, control and expression of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase activities in human breast cancer.
Breast Neoplasms
Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells.
Breast Neoplasms
Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
Breast Neoplasms
Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
Breast Neoplasms
Sex steroid-producing enzymes in human breast cancer.
Breast Neoplasms
Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.
Breast Neoplasms
Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+.
Breast Neoplasms
Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Breast Neoplasms
Synergistic interaction of growth factors and albumin in regulating estradiol synthesis in breast cancer cells.
Breast Neoplasms
The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.
Breast Neoplasms
The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells.
Breast Neoplasms
The effect of breast tumour and normal breast tissue cytosols on oestradiol 17 beta-hydroxysteroid dehydrogenase activity.
Breast Neoplasms
The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment.
Breast Neoplasms
The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Breast Neoplasms
The regulation of hydroxysteroid 17?-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer.
Breast Neoplasms
The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue.
Breast Neoplasms
The role and proposed mechanism by which oestradiol 17 beta-hydroxysteroid dehydrogenase regulates breast tumour oestrogen concentrations.
Breast Neoplasms
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells.
Breast Neoplasms
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Breast Neoplasms
The SEEM: selective estrogen enzyme modulators in breast cancer.
Breast Neoplasms
The selective estrogen enzyme modulator (SEEM) in breast cancer.
Breast Neoplasms
The selective estrogen enzyme modulators in breast cancer: a review.
Breast Neoplasms
Two non-reactive ternary complexes of estrogenic 17beta-hydroxysteroid dehydrogenase: crystallization and preliminary structural analysis.
Breast Neoplasms
[Actions of a 19-norprogesterone derivative on mammary gland: nomegestrol acetate]
Breast Neoplasms
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
Breast Neoplasms
[Evaluation of 17-beta-hydroxysteroid dehydrogenase activity as a marker of the hormone dependence of breast cancers]
Carcinoma
16 alpha-iodo-3,17 beta-estradiol: a stable ligand for estrogen receptor determinations in tissues with high 17 beta-hydroxysteroid dehydrogenase activity.
Carcinoma
17 beta-hydroxysteroid dehydrogenase deficiency in malignant interstitial cell carcinoma of the testis.
Carcinoma
Adrenocortical cytopathology.
Carcinoma
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Carcinoma
Characterization of rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues.
Carcinoma
Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in the rat: a model of postmenopausal breast cancer.
Carcinoma
Estradiol and progestin receptors, 17-beta-hydroxysteroid-dehydrogenase and histopathologic grade in endometrial carcinoma.
Carcinoma
Expression of human 17 beta-hydroxysteroid dehydrogenase in mammalian cells.
Carcinoma
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Carcinoma
Partial purification and evidence for heterogeneity of the cytoplasmic 17beta-hydroxysteroid dehydrogenase (17beta-HSD) from normal human endometrium and endometrical carcinoma.
Carcinoma
Steroid biosynthesis in human adrenal tumors.
Carcinoma
Steroid-converting enzymes in human ovarian carcinomas.
Carcinoma
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
Carcinoma
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Carcinoma, Ductal
17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Carcinoma, Ductal
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Carcinoma, Embryonal
Evidence of 3 beta-hydroxysteroid dehydrogenase activity in several murine embryonal carcinoma cell lines.
Carcinoma, Endometrioid
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Carcinoma, Endometrioid
The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma.
Carcinoma, Hepatocellular
17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver.
Carcinoma, Hepatocellular
Association of Genetic Polymorphisms in HSD17B1, HSD17B2 and SHBG Genes with Hepatocellular Carcinoma Risk.
Carcinoma, Hepatocellular
Deletion mapping of chromosome 16q24 in hepatocellular carcinoma in Taiwan and mutational analysis of the 17-beta-HSD gene localized to the region.
Carcinoma, Intraductal, Noninfiltrating
17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Carcinoma, Intraductal, Noninfiltrating
Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast.
Carcinoma, Intraductal, Noninfiltrating
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Carcinoma, Ovarian Epithelial
Steroid-converting enzymes in human ovarian carcinomas.
Cholera
Hormonal regulation of androgen biosynthesis by primary cultures of testis cells from neonatal rats.
cholesterol monooxygenase (side-chain-cleaving) deficiency
17 alpha-hydroxylation deficiency.
Choriocarcinoma
17 beta-Hydroxysteroid dehydrogenase: enzymatic activity and mRNA species in choriocarcinoma cells.
Choriocarcinoma
Characterization of 17 beta-hydroxysteroid dehydrogenase type 1 in choriocarcinoma cells: regulation by basic fibroblast growth factor.
Choriocarcinoma
Phosphorylation of 17 beta-hydroxysteroid dehydrogenase in BeWo choriocarcinoma cells.
Choriocarcinoma
Regulation of 17 beta-hydroxysteroid dehydrogenase type 1 by epidermal growth factor and transforming growth factor-alpha in choriocarcinoma cells.
Choriocarcinoma
Regulation of 3 beta-hydroxysteroid dehydrogenase and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels by cyclic adenosine 3',5'-monophosphate and phorbol myristate acetate in human choriocarcinoma cells.
Choriocarcinoma
Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells.
Choriocarcinoma
Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Choriocarcinoma
The proximal promoter region of the gene encoding human 17beta-hydroxysteroid dehydrogenase type 1 contains GATA, AP-2, and Sp1 response elements: analysis of promoter function in choriocarcinoma cells.
Choriocarcinoma
[Regulation of human 17 beta-hydroxysteroid dehydrogenase type 1 expression by cyclic adenosine 3',5'-monophosphate in choriocarcinoma cells]
Colonic Neoplasms
17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.
Colonic Neoplasms
Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer.
Colonic Neoplasms
Oestrogen inactivation in the colon: analysis of the expression and regulation of 17beta-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer.
Colorectal Neoplasms
Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk.
Cryptorchidism
Influence of experimental cryptorchidism on cholesterol side-chain cleavage enzyme and delta5-3beta-hydroxysteroid dehydrogenase activities in rat testes.
Cryptorchidism
Phospholipid hydroperoxide glutathione peroxidase is involved in the maintenance of male fertility under cryptorchidism in mice.
Cushing Syndrome
Enzyme histo-cytochemical studies in human adrenocortical adenomas. [II] Cushing's syndrome.
Cushing Syndrome
Experience with trilostane in the treatment of Cushing's syndrome.
Cushing Syndrome
Investigation of urinary steroid profiles as a diagnostic method in Cushing's syndrome.
Cushing Syndrome
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
Cushing Syndrome
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Cushing Syndrome
Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
Cushing Syndrome
Trilostane and the normal hypothalamic-pituitary-testicular axis.
Cushing Syndrome
[Effect of a 3 beta-hydroxysteroid dehydrogenase inhibitor (trilostane) on Cushing's syndrome]
Cystic Fibrosis
Regulation of Wolffian duct development.
Cysts
Changes in the forward and reverse metabolism of aromatizable androgens during the development of large ovarian cysts in the pregnant rat.
Cysts
Dominant bovine ovarian follicular cysts express increased levels of messenger RNAs for luteinizing hormone receptor and 3 beta-hydroxysteroid dehydrogenase delta(4),delta(5) isomerase compared to normal dominant follicles.
Cysts
Molecular characterisation of two novel 17beta-hydroxysteroid dehydrogenase genes from the soybean cyst nematode Heterodera glycines
Cysts
Private inherited microdeletion/microduplications: implications in clinical practice.
Diabetes Mellitus, Type 1
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Diabetes Mellitus, Type 2
Genetic variants in HSD17B3, SMAD3, and IPO11 impact circulating lipids in response to fenofibrate in individuals with type 2 diabetes.
Diabetes Mellitus, Type 2
[Ginkgo biloba extract enhances testosterone synthesis of Leydig cells in type 2 diabetic rats]
Disorder of Sex Development, 46,XY
17 alpha-hydroxylation deficiency.
Disorder of Sex Development, 46,XY
17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations.
Disorder of Sex Development, 46,XY
Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics.
Disorder of Sex Development, 46,XY
Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3).
Disorder of Sex Development, 46,XY
Dihydrotestosterone binding by cultured human fibroblasts. Comparison of cells from control subjects and from patients with hereditary male pseudohermaphroditism due to androgen resistance.
Disorder of Sex Development, 46,XY
Familial male pseudohermaphroditism with gynaecomastia due to 17 beta-hydroxysteroid dehydrogenase deficiency. A report of 3 cases.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism caused by nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: gender reassignment in early infancy.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: studies on the natural history of the defect and effect of androgens on gender role.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to 3 beta-hydroxysteroid dehydrogenase-isomerase deficiency associated with atrial septal defect.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: gender role change and absence of gynecomastia at puberty.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty.
Disorder of Sex Development, 46,XY
Masculinizing genitoplasty in intersex patients.
Disorder of Sex Development, 46,XY
Mechanisms of androgen production in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
Disorder of Sex Development, 46,XY
Mutation in the human gene for 3 beta-hydroxysteroid dehydrogenase type II leading to male pseudohermaphroditism without salt loss.
Disorder of Sex Development, 46,XY
Neutral 17beta-hydroxysteroid oxidoreductase deficiency in testes causing male pseudohermaphroditism in an infant.
Disorder of Sex Development, 46,XY
Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene.
Disorder of Sex Development, 46,XY
Proceedings: 17beta-hydroxysteroid oxidoreductase deficiency causing male pseudohermaphroditism in a child.
Disorder of Sex Development, 46,XY
Ten years experience with masculinizing genitoplasty in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
Disorder of Sex Development, 46,XY
[Elevated levels of plasma 4-ene steroids in a case of congenital deficiency of 3 beta-hydroxysteroid dehydrogenase]
Disorder of Sex Development, 46,XY
[Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency]
Disorders of Sex Development
17?-Hydroxysteroid dehydrogenase 3 deficiency: Three case reports and a systematic review.
Disorders of Sex Development
A (R80Q) mutation in 17 beta-hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is associated with pseudohermaphroditism in males and normal asymptomatic females.
Disorders of Sex Development
A Novel Nonsense Mutation in HSD17B3 Gene in a Tunisian Patient with Sexual Ambiguity.
Disorders of Sex Development
Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase.
Disorders of Sex Development
Biochemical analyses and molecular modeling explain the functional loss of 17?-hydroxysteroid dehydrogenase 3 mutant G133R in three Tunisian patients with 46, XY Disorders of Sex Development.
Disorders of Sex Development
Biochemical Analysis of Four Missense Mutations in the HSD17B3 Gene Associated With 46,XY Disorders of Sex Development in Egyptian Patients.
Disorders of Sex Development
Characterization of two novel homozygous missense mutations involving codon 6 and 259 of type II 3beta-hydroxysteroid dehydrogenase (3betaHSD) gene causing, respectively, nonsalt-wasting and salt-wasting 3betaHSD deficiency disorder.
Disorders of Sex Development
Complexities of gender assignment in 17beta-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for early orchiectomy?
Disorders of Sex Development
Mutation in 3 beta-hydroxysteroid dehydrogenase type II associated with pseudohermaphroditism in males and premature pubarche or cryptic expression in females.
Disorders of Sex Development
Novel cases of Tunisian patients with mutations in the gene encoding 17?-hydroxysteroid dehydrogenase type 3 and a founder effect.
Disorders of Sex Development
Novel mutations of HSD17B3 in three Chinese patients with 46,XY Disorders of Sex Development.
Disorders of Sex Development
Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls.
Disorders of Sex Development
Progressive virilization of a pubertal phenotypic female: 17 beta-hydroxysteroid dehydrogenase deficiency.
Disorders of Sex Development
The novel founder homozygous V225M mutation in the HSD17B3 gene causes aberrant splicing and XY-DSD.
Disorders of Sex Development
Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women.
Disorders of Sex Development
Use of laparoscopy in intersex patients.
Disorders of Sex Development
[Case report: congenital adrenal hyperplasia and ambiguous genitalia due to 3 beta-hydroxysteroid dehydrogenase deficiency]
Down Syndrome
Polymorphisms in HSD17B1: Early Onset and Increased Risk of Alzheimer's Disease in Women with Down Syndrome.
Endometrial Hyperplasia
In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia.
Endometrial Hyperplasia
Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice.
Endometrial Hyperplasia
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
Endometrial Hyperplasia
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Endometrial Neoplasms
17 beta-Hydroxysteroid dehydrogenase activity in endometrial cancer cells: different metabolic pathways of estradiol in hormone-responsive and non-responsive intact cells.
Endometrial Neoplasms
Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer.
Endometrial Neoplasms
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Endometrial Neoplasms
Estrogen formation in endometrial and cervix cancer cell lines: Involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12).
Endometrial Neoplasms
Interaction of soy and 17beta-HSD1 gene polymorphisms in the risk of endometrial cancer.
Endometrial Neoplasms
Leydig cell tumor of the ovary associated with endometrial carcinoma and containing 17 beta-hydroxysteroid dehydrogenase.
Endometrial Neoplasms
Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
Endometrial Neoplasms
On the mitochondrial 17beta-hydroxysteroid dehydrogenase from human endometrium and endometrial carcinoma: characterization and intramitochondrial distribution.
Endometrial Neoplasms
Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer.
Endometrial Neoplasms
Short-term effects of danazol and medroxyprogesterone acetate on cytosol and nuclear estrogen and progestin receptors, 17 beta-hydroxysteroid dehydrogenase activity, histopathology, and ultrastructure of human endometrial adenocarcinoma.
Endometrial Neoplasms
Studies on 17 beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma. III. Partial purification and characterization of the microsomal enzyme.
Endometrial Neoplasms
Studies on 17beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma I. Subcellular distribution and variations of specific enzyme activity.
Endometrial Neoplasms
Studies on 17beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma.
Endometrial Neoplasms
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Endometrial Neoplasms
The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma.
Endometrial Neoplasms
The role of tissue steroids in regulating aromatase and oestradiol 17 beta-hydroxysteroid dehydrogenase activities in breast and endometrial cancer.
Endometrial Neoplasms
[Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)]
Endometriosis
Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection.
Endometriosis
Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19.
Endometriosis
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Endometriosis
Association of endometriosis risk and genetic polymorphisms involving biosynthesis of sex steroids and their receptors: an updating meta-analysis.
Endometriosis
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.
Endometriosis
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
Endometriosis
Effect of gestrinone in endometriosis tissue and endometrium.
Endometriosis
Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line.
Endometriosis
Endometriosis expresses a molecular pattern consistent with decreased retinoid uptake, metabolism and action.
Endometriosis
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Endometriosis
Endometriosis: the ultimate hormonal disease.
Endometriosis
Estrogen metabolizing enzymes in endometrium and endometriosis.
Endometriosis
Estrogen production and metabolism in endometriosis.
Endometriosis
Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Endometriosis
Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis.
Endometriosis
Expression of 17beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis.
Endometriosis
Functional analyses of endometriosis-related polymorphisms in the estrogen synthesis and metabolism-related genes.
Endometriosis
HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in infertile women with endometriosis.
Endometriosis
Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Endometriosis
Involvement of 17?-hydroxysteroid dehydrogenase type gene 1 937 A>G polymorphism in infertility in Polish Caucasian women with endometriosis.
Endometriosis
Mechanisms of excessive estrogen formation in endometriosis.
Endometriosis
Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.
Endometriosis
Progesterone's role in deep infiltrating endometriosis: Progesterone receptor and estrogen metabolism enzymes expression and physiological changes in primary endometrial stromal cell culture.
Endometriosis
Role of aromatase in endometrial disease.
Endometriosis
Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.
Endometriosis
Steroidal regulation of endometriosis tissue: lack of induction of 17 beta-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol.
Endometriosis
Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis.
Endometriosis
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Essential Hypertension
The inhibiting effect of trilostane on testosterone synthesis. Hormonal and morphologic alterations induced by subchronic trilostane treatment in rats and healthy volunteers.
Fetal Growth Retardation
Estrogen-related receptor ? regulates expression of 17?-hydroxysteroid dehydrogenase type 1 in fetal growth restriction.
Fibroadenoma
Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas.
Fibroma
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
Follicular Cyst
Dominant bovine ovarian follicular cysts express increased levels of messenger RNAs for luteinizing hormone receptor and 3 beta-hydroxysteroid dehydrogenase delta(4),delta(5) isomerase compared to normal dominant follicles.
Follicular Cyst
Late-onset 3 beta-hydroxysteroid dehydrogenase deficiency with virilization induced by a large ovarian cyst.
Fowlpox
Deletion of fowlpox virus homologues of vaccinia virus genes between the 3 beta-hydroxysteroid dehydrogenase (A44L) and DNA ligase (A50R) genes.
Genetic Diseases, Inborn
Molecular genetics of androgenic 17 beta-hydroxysteroid dehydrogenases.
Genetic Diseases, Inborn
The molecular biology of androgenic 17 beta-hydroxysteroid dehydrogenases.
Glioma
Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
The influence of haemoglobin-S and G6PD deficiency on the activity of the 17 beta-hydroxysteroid dehydrogenase of intact human erythrocytes.
Glucosephosphate Dehydrogenase Deficiency
The influence of haemoglobin-S and G6PD deficiency on the activity of the 17 beta-hydroxysteroid dehydrogenase of intact human erythrocytes.
Goiter
Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.
Gonadal Dysgenesis
46,XX pure gonadal dysgenesis with growth hormone deficiency and impaired 3 beta-hydroxysteroid dehydrogenase activity.
Gonadal Dysgenesis
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Gonadal Dysgenesis, Mixed
Masculinizing genitoplasty in intersex patients.
Gonadal Dysgenesis, Mixed
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Gonadal Dysgenesis, Mixed
Use of laparoscopy in intersex patients.
Gynecomastia
17-?-Hydroxysteroid Dehydrogenase Type 3 Deficiency in Three Adult Iranian Siblings.
Gynecomastia
Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: gender role change and absence of gynecomastia at puberty.
Gynecomastia
Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male.
Gynecomastia
Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17.
Heart Failure
A case of neonatal McCune-Albright syndrome with Cushing syndrome and hyperthyroidism.
Heart Septal Defects, Atrial
Male pseudohermaphroditism due to 3 beta-hydroxysteroid dehydrogenase-isomerase deficiency associated with atrial septal defect.
Hepatitis, Chronic
17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver.
Herpes Zoster
Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies.
Herpes Zoster
Histochemical observations on the adrenal gland of bat Vesperugo pipistrellus (Dobson).
Herpes Zoster
Serum steroids and success of corticotropin therapy in infantile spasms.
Herpes Zoster
Spatiotemporal changes in cytokeratin expression in the neonatal rat ovary.
Herpes Zoster
Studies of adrenal steroidogenic enzymes in guinea pigs.
Herpes Zoster
The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3 beta-hydroxysteroid dehydrogenase.
Hirsutism
Congenital adrenal hyperplasia.
Hirsutism
Hirsutism due to late onset 3 beta-hydroxysteroid dehydrogenase deficiency.
Hirsutism
Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women.
Hirsutism
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency in children with accelerated growth, premature pubarche and/or hirsutism.
Hirsutism
No genetic mutation in type II 3 beta-hydroxysteroid dehydrogenase gene in patients with biochemical evidence of enzyme deficiency.
Hirsutism
Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency in young girls with hirsutism and premature pubarche.
Hirsutism
Normal ovarian function in a mild form of late-onset 3 beta-hydroxysteroid dehydrogenase deficiency.
Hirsutism
Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male.
Hirsutism
Serum and urinary steroids in girls with precocious pubarche and/or hirsutism due to mild 3-beta-hydroxysteroid dehydrogenase deficiency.
Hirsutism
The human 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene cluster on chromosome 1p13 contains a presumptive pseudogene; 3 beta-HSD and CYP17 do not segregate with dominantly inherited hirsutism.
Hirsutism
The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia.
Hirsutism
[3 beta-hydroxysteroid dehydrogenase deficiency and 21-hydroxylase deficiency in hirsutism]
Hirsutism
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
Hydatidiform Mole
Kinetic analysis of 3 beta-hydroxysteroid dehydrogenase activity in microsomes from complete hydatidiform mole.
Hydatidiform Mole
Plasma hormone concentrations and serum 17 beta-hydroxysteroid dehydrogenase activity in molar pregnancy.
Hyperaldosteronism
Inhibition of furosemide-induced kaliuresis in the rat by trilostane, an inhibitor of adrenal steroidogenesis.
Hyperaldosteronism
Long-term treatment of idiopathic hyperaldosteronism using trilostane.
Hyperaldosteronism
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency with hyperaldosteronism.
Hyperaldosteronism
Primary aldosteronism: treatment with trilostane.
Hyperaldosteronism
The inhibiting effect of trilostane on testosterone synthesis. Hormonal and morphologic alterations induced by subchronic trilostane treatment in rats and healthy volunteers.
Hyperandrogenism
3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism.
Hyperandrogenism
Hyperandrogenism due to 3 beta-hydroxysteroid dehydrogenase deficiency with accessory adrenocortical tissue: a hormonal and metabolic evaluation.
Hyperandrogenism
Hyperandrogenism: new insights into etiology, diagnosis, and therapy.
Hyperandrogenism
Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome.
Hyperandrogenism
The incidence of late-onset congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency among hirsute women.
Hyperandrogenism
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
Hyperprolactinemia
Metoclopramide-induced hyperprolactinaemia: effects on corpus luteum function, endometrial steroid receptor concentrations and 17 beta-hydroxysteroid dehydrogenase activity.
Hyperprolactinemia
Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia.
Hyperprolactinemia
Prolactin has a direct effect on adrenal androgen secretion.
Hyperprolactinemia
Regulation of 3 beta-hydroxysteroid dehydrogenase activity in rat testis under hyperprolactinemia and excessive 17 beta-estradiol.
Hyperprolactinemia
The effects of prolactin on rat ovarian function.
Hyperprolactinemia
The effects of prolactin on rat testicular steroidogenic enzyme activities.
Hypertension
Plasma level of hydroxysteroid (17-?) dehydrogenase 1 in the second trimester is an independent risk factor for predicting preeclampsia after adjusting for the effects of mean blood pressure, bilateral notching and plasma level of soluble fms-like tyrosine kinase 1/placental growth factor ratio.
Hypertension
Steroid characteristics of mineralocorticoid adrenocortical hypertension.
Hypogonadism
[Clinical features and diagnosis of mild 3-beta-hydroxysteroid dehydrogenase deficiency in men]
Hypogonadism
[Disorder of 17 beta-hydroxysteroid dehydrogenase as the cause of hypergonadotropic hypogonadism in 2 siblings with primary amenorrhea]
Hypospadias
Genetic Polymorphisms of 17beta-Hydroxysteroid Dehydrogenase 3 and the Risk of Hypospadias.
Hypospadias
Genotype-phenotype correlation and identification of two novel SRD5A2 mutations in 33 Chinese patients with hypospadias.
Hypospadias
Molecular study of the 3 beta-hydroxysteroid dehydrogenase gene type II in patients with hypospadias.
Hypospadias
The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias.
Infertility
Congenital adrenal hyperplasia.
Infertility
Deleting the mouse Hsd17b1 gene results in a hypomorphic Naglu allele and a phenotype mimicking a lysosomal storage disease.
Infertility
Involvement of 17?-hydroxysteroid dehydrogenase type gene 1 937 A>G polymorphism in infertility in Polish Caucasian women with endometriosis.
Infertility
Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.
Infertility
[17 beta hydroxysteroid dehydrogenase and creatine phosphokinase activities and the levels of sex hormones and their receptors in the uterus of patients with fibromyoma or endocrine sterility]
Infertility
[Clinical features and diagnosis of mild 3-beta-hydroxysteroid dehydrogenase deficiency in men]
Insulin Resistance
Steroidogenic alterations and adrenal androgen excess in PCOS.
Klinefelter Syndrome
Masculinizing genitoplasty in intersex patients.
Leber Congenital Amaurosis
Retinol dehydrogenases RDH11 and RDH12 in the mouse retina: expression levels during development and regulation by oxidative stress.
Leiomyoma
17 beta-hydroxysteroid dehydrogenase activity in leiomyoma and myometrium and its relationship to concentrations of oestrone, oestradiol and progesterone throughout the menstrual cycle.
Leiomyoma
Aromatase and leiomyoma of the uterus.
Leiomyoma
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Leiomyoma
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Leiomyoma
In vitro conversion of estradiol-17beta into estrone in normal human myometrium and leiomyoma.
Leiomyoma
Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma.
Leiomyoma
Polymorphisms in genes HSD17B1 and HSD17B2 and uterine leiomyoma risk in Chinese women.
Leiomyoma
[17 beta hydroxysteroid dehydrogenase and creatine phosphokinase activities and the levels of sex hormones and their receptors in the uterus of patients with fibromyoma or endocrine sterility]
Leukemia
Differential gene regulation by estrogen and progesterone in the primate endometrium.
Leukemia
Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells.
Leydig Cell Tumor
Histogenesis, cytodifferentiation, and its subcellular steroidogenic sites in the virilizing ovarian Leydig cell tumor: light microscopic dry-mounting radioautography for [3H]cholesterol and electron microscopic cytochemistry for 3 beta-hydroxysteroid dehydrogenase activity.
Leydig Cell Tumor
Leydig cell tumor of the ovary associated with endometrial carcinoma and containing 17 beta-hydroxysteroid dehydrogenase.
Liver Diseases
Hydroxylation and sulfation of sex steroid hormones in inflammatory liver.
Lymphatic Metastasis
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Lymphatic Metastasis
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Lysosomal Storage Diseases
Deleting the mouse Hsd17b1 gene results in a hypomorphic Naglu allele and a phenotype mimicking a lysosomal storage disease.
Melanoma
Sebocytes are the key regulators of androgen homeostasis in human skin.
Meningioma
17 beta-Hydroxysteroid dehydrogenase activity correlates with the type-2 17 beta-hydroxysteroid dehydrogenase mRNA abundance in human meningioma tumors.
Meningioma
Biochemical characterization of 17 beta-hydroxysteroid dehydrogenase in human meningioma.
Meningioma
Characterization of 17 beta-hydroxysteroid dehydrogenase activity and mRNA abundance in human meningioma tumors.
Mineralocorticoid Excess Syndrome, Apparent
Steroid characteristics of mineralocorticoid adrenocortical hypertension.
Neoplasm Metastasis
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Neoplasm Metastasis
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Neoplasm Metastasis
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasms
17 beta-Hydroxysteroid dehydrogenase activity correlates with the type-2 17 beta-hydroxysteroid dehydrogenase mRNA abundance in human meningioma tumors.
Neoplasms
17 beta-hydroxysteroid dehydrogenase in common epithelial ovarian tumors.
Neoplasms
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Neoplasms
A virilizing adrenal tumor with borderline elevation of urinary 17-ketosteroids and histochemical demonstration of a deficiency in the delta 5/delta 4-isomerase, 3 beta-hydroxysteroid dehydrogenase enzymatic system.
Neoplasms
A virilizing adrenocortical tumor in a female infant: in vivo and in vitro biochemical characteristics.
Neoplasms
Acid phosphatases of dog testis and a Leydig cell tumor.
Neoplasms
Amplification of HSD17B1 and ERBB2 in primary breast cancer.
Neoplasms
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Neoplasms
Aromatase and intracrinology of estrogen in hormone-dependent tumors.
Neoplasms
Aromatase inhibitor development for treatment of breast cancer.
Neoplasms
Characterization of 17 beta-hydroxysteroid dehydrogenase activity and mRNA abundance in human meningioma tumors.
Neoplasms
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary.
Neoplasms
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in normal and carcinomatous endometrium.
Neoplasms
Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21.
Neoplasms
Determinants of tissue oestradiol levels in human breast cancer.
Neoplasms
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase Type 3.
Neoplasms
Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in the rat: a model of postmenopausal breast cancer.
Neoplasms
Effects of LH and oestrogen on the growth of feminising testicular tumours in mice.
Neoplasms
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Neoplasms
Establishment and further characterization of a line of transgenic mice showing testicular tumorigenesis at 100% incidence.
Neoplasms
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Neoplasms
Estradiol and progestin receptors, 17-beta-hydroxysteroid-dehydrogenase and histopathologic grade in endometrial carcinoma.
Neoplasms
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Neoplasms
Estrogen inhibits cell proliferation through in situ production in human thymoma.
Neoplasms
Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer.
Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.
Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Neoplasms
Expression of COX-2 and steroid converting enzymes in breast cancer.
Neoplasms
Expression of human 17 beta-hydroxysteroid dehydrogenase in mammalian cells.
Neoplasms
Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer.
Neoplasms
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies.
Neoplasms
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Neoplasms
High mRNA levels of 17?-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer.
Neoplasms
Histogenesis, cytodifferentiation, and its subcellular steroidogenic sites in the virilizing ovarian Leydig cell tumor: light microscopic dry-mounting radioautography for [3H]cholesterol and electron microscopic cytochemistry for 3 beta-hydroxysteroid dehydrogenase activity.
Neoplasms
HPLC-RIA analysis of steroid hormone profile in a virilizing stromal tumor of the ovary.
Neoplasms
HSD17B1 gene polymorphisms and risk of endometrial and breast cancer.
Neoplasms
Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts.
Neoplasms
Immunohistochemical and biochemical analysis of a human Sertoli-Leydig cell tumor: autonomous steroid production characteristic of ovarian theca cells.
Neoplasms
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
Neoplasms
In vitro pregnenolone metabolism by mouse adrenal gland: II-Biosynthesis of androgens.
Neoplasms
In vivo mouse model for analysis of hydroxysteroid (17beta) dehydrogenase 1 inhibitors.
Neoplasms
Increased 17 beta-hydroxysteroid dehydrogenase activity in a masculinizing adrenal adenoma in a patient with isolated testosterone overproduction.
Neoplasms
Inhibin and activin differentially regulate androgen production and 17 alpha-hydroxylase expression in human ovarian thecal-like tumor cells.
Neoplasms
Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
Neoplasms
Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Neoplasms
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
Neoplasms
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
Neoplasms
Leydig cell tumor of the ovary associated with endometrial carcinoma and containing 17 beta-hydroxysteroid dehydrogenase.
Neoplasms
Loss of estrogen inactivation in colonic cancer.
Neoplasms
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasms
Measurement of steroidogenesis in rodent Leydig cells: a comparison between pregnenolone and testosterone production.
Neoplasms
Metabolism of estradiol by human breast cancer.
Neoplasms
Molecular Framework of Steroid/Retinoid Discrimination in 17beta-Hydroxysteroid Dehydrogenase Type 1 and Photoreceptor-associated Retinol Dehydrogenase.
Neoplasms
New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -benzenes: Influence of Additional Substituents on 17beta-Hydroxysteroid Dehydrogenase Type 1 (17beta-HSD1) Inhibitory Activity and Selectivity.
Neoplasms
Novel insight in estrogen homeostasis and bioactivity in the ACI rat model of estrogen-induced mammary gland carcinogenesis.
Neoplasms
Oxidations of 17beta-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or beta-naphthoflavone.
Neoplasms
Polymorphism of HSD17B1 Ser312Gly with Cancer Risk: Evidence from 66,147 Subjects.
Neoplasms
Presence of 17 beta-hydroxysteroid dehydrogenase type 3 messenger ribonucleic acid transcript in an ovarian Sertoli-Leydig cell tumor.
Neoplasms
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Neoplasms
Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue.
Neoplasms
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Neoplasms
Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer.
Neoplasms
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Neoplasms
siRNA-based breast cancer therapy by suppressing 17?-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo.
Neoplasms
Small adrenocortical tumors without apparent clinical endocrine abnormalities. Immunolocalization of steroidogenic enzymes.
Neoplasms
Steroid biosynthesis in human adrenal tumors.
Neoplasms
Steroid cell tumor associated with primary amenorrhea and virilization.
Neoplasms
Steroid metabolism by a tumour of the specific gonadal stroma in a child.
Neoplasms
Steroid metabolism by normal and neoplastic parotid tissue.
Neoplasms
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution.
Neoplasms
Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Neoplasms
The effect of ethynyloestradiol and medroxyprogesterone acetate on the in vivo uptake and metabolism of 3H-oestradiol by breast tumour tissue in postmenopausal women.
Neoplasms
The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model.
Neoplasms
The effects of hydrogen peroxide on steroidogenesis in mouse Leydig tumor cells.
Neoplasms
The mouse inhibin alpha-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice.
Neoplasms
The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium.
Neoplasms
The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer.
Neoplasms
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Neoplasms
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Neoplasms
Type beta 1 transforming growth factor is an inhibitor of 3 beta-hydroxysteroid dehydrogenase isomerase in mouse adrenal tumor cell line Y1.
Neoplasms
Young female patient with testosterone-producing adrenocortical adenoma also showing signs of subclinical Cushing's syndrome.
Neoplasms
[Abnormal expression of genes that regulate retinoid metabolism and signaling in non-small-cell lung cancer].
Neoplasms
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
Neoplasms
[Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)]
Neoplasms
[Expression of human 17 beta-hydroxysteroid dehydrogenase gene in BmNPV expression system]
Neoplasms
[Metabolism of androgens in various histological variants of bone tumors]
Obesity
Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5.
Osteoarthritis
Estrogen metabolism, not biosynthesis, in rabbit articular cartilage and isolated chondrocytes: a preliminary study.
Osteosarcoma
17Beta-hydroxysteroid dehydrogenases in human bone cells.
Ovarian Cysts
Changes in the forward and reverse metabolism of aromatizable androgens during the development of large ovarian cysts in the pregnant rat.
Ovarian Cysts
Late-onset 3 beta-hydroxysteroid dehydrogenase deficiency with virilization induced by a large ovarian cyst.
Ovarian Diseases
Experimental micropolycystic ovarian disease. I. Measurement of body weight, ovarian weight and histochemical activity of 17 beta-hydroxysteroid dehydrogenase.
Ovarian Diseases
Polycystic ovarian disease and congenital and late-onset adrenal hyperplasia.
Ovarian Diseases
The response of several adrenocortical steroids to the administration of ACTH in hirsute women.
Ovarian Neoplasms
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Ovarian Neoplasms
Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Ovarian Neoplasms
Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Peripheral Nerve Injuries
Increased expression of 3 beta-hydroxysteroid dehydrogenase mRNA in dorsal root ganglion neurons of adult rats following peripheral nerve injury.
Peroxisomal Disorders
Molecular changes in the D-bifunctional protein cDNA sequence in Australasian patients belonging to the bifunctional protein complementation group.
Pituitary ACTH Hypersecretion
Concomitant falls of plasma cortisol and ACTH levels in a case of Cushing's disease during treatment with trilostane.
Pituitary ACTH Hypersecretion
The inhibiting effect of trilostane on testosterone synthesis. Hormonal and morphologic alterations induced by subchronic trilostane treatment in rats and healthy volunteers.
Pituitary Neoplasms
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
Polycystic Ovary Syndrome
5 alpha-reductase activity in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Polycystic Ovary Syndrome
Polycystic ovary syndrome: evidence for reduced 3 beta-hydroxysteroid dehydrogenase gene expression in human luteinizing granulosa cells.
Polycystic Ovary Syndrome
The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.
Polycystic Ovary Syndrome
[Partial 3-beta-hydroxysteroid dehydrogenase deficiencies]
Polycythemia
Serum testosterone levels and excessive erythrocytosis during the process of adaptation to high altitudes.
Polyendocrinopathies, Autoimmune
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Pregnancy, Tubal
Expression of P450 aromatase and 17beta-hydroxysteroid dehydrogenase type 1 at fetal-maternal interface during tubal pregnancy.
Prolactinoma
Altered profile of endogenous steroids in the urine of patients with prolactinoma.
Prostatic Hyperplasia
17 beta-Hydroxysteroid dehydrogenase in the human prostate: properties and distribution between epithelium and stroma in benign hyperplastic tissue.
Prostatic Hyperplasia
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Prostatic Hyperplasia
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Prostatic Hyperplasia
Expression of enzymes involved in estrogen metabolism in human prostate.
Prostatic Hyperplasia
Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids.
Prostatic Hyperplasia
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Prostatic Intraepithelial Neoplasia
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Prostatic Neoplasms
17beta-hydroxysteroid dehydrogenase type 11 (Pan1b) expression in human prostate cancer.
Prostatic Neoplasms
3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Prostatic Neoplasms
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Prostatic Neoplasms
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Prostatic Neoplasms
Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men.
Prostatic Neoplasms
Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Prostatic Neoplasms
Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
Prostatic Neoplasms
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase Type 3.
Prostatic Neoplasms
Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.
Prostatic Neoplasms
Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues.
Prostatic Neoplasms
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Prostatic Neoplasms
Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells.
Prostatic Neoplasms
Genetic susceptibility to cancer from exogenous and endogenous exposures.
Prostatic Neoplasms
Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer.
Prostatic Neoplasms
Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk.
Prostatic Neoplasms
In situ androgen producing enzymes in human prostate cancer.
Prostatic Neoplasms
Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells.
Prostatic Neoplasms
Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
Prostatic Neoplasms
Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue.
Prostatic Neoplasms
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Prostatic Neoplasms
Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human prostate cancer cells.
Prostatic Neoplasms
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer.
Prostatic Neoplasms
Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.
Prostatic Neoplasms
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth.
Prostatic Neoplasms
Steroidogenic enzymes and stem cell markers are up-regulated during androgen deprivation in prostate cancer.
Prostatic Neoplasms
The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Pulmonary Disease, Chronic Obstructive
Increased levels of enzymes involved in local estradiol synthesis in chronic obstructive pulmonary disease.
Retinal Dystrophies
Retinol dehydrogenases RDH11 and RDH12 in the mouse retina: expression levels during development and regulation by oxidative stress.
Retinitis Pigmentosa
New syndrome with retinitis pigmentosa is caused by nonsense mutations in retinol dehydrogenase RDH11.
Sertoli-Leydig Cell Tumor
Presence of 17 beta-hydroxysteroid dehydrogenase type 3 messenger ribonucleic acid transcript in an ovarian Sertoli-Leydig cell tumor.
Sex Cord-Gonadal Stromal Tumors
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
Smallpox
Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus.
Starvation
Effects of starvation in rats on serum levels of testosterone, dihydrotestosterone and testicular 3 beta-hydroxysteroid dehydrogenase activity.
steroid 11beta-monooxygenase deficiency
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
steroid 11beta-monooxygenase deficiency
Congenital adrenal hyperplasia in pregnancy.
steroid 11beta-monooxygenase deficiency
Congenital adrenal hyperplasia in Turkey: a review of 273 patients.
steroid 11beta-monooxygenase deficiency
Congenital adrenal hyperplasia.
steroid 11beta-monooxygenase deficiency
Defects in steroidogenic enzymes. Discrepancies between clinical steroid research and molecular biology results.
steroid 11beta-monooxygenase deficiency
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
steroid 11beta-monooxygenase deficiency
Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
steroid 21-monooxygenase deficiency
3 alpha-Androstanediol glucuronide in premature and normal pubarche.
steroid 21-monooxygenase deficiency
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
steroid 21-monooxygenase deficiency
Congenital adrenal hyperplasia in pregnancy.
steroid 21-monooxygenase deficiency
Congenital adrenal hyperplasia.
steroid 21-monooxygenase deficiency
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
steroid 21-monooxygenase deficiency
Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women.
steroid 21-monooxygenase deficiency
[3 beta-hydroxysteroid dehydrogenase deficiency and 21-hydroxylase deficiency in hirsutism]
Stiff-Person Syndrome
Stiff-man syndrome: identification of 17 beta-hydroxysteroid dehydrogenase type 4 as a novel 80-kDa antineuronal antigen.
Stomach Neoplasms
Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival.
Stomach Neoplasms
Expression of 17?-hydroxysteroid dehydrogenase type 1 in gastric cancer.
Stomach Neoplasms
Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.
Testicular Neoplasms
Effect modification of endocrine disruptors and testicular germ cell tumour risk by hormone-metabolizing genes.
testosterone 17beta-dehydrogenase (nadp+) deficiency
Clinical, endocrine, and molecular findings in 17beta-hydroxysteroid dehydrogenase type 3 deficiency.
testosterone 17beta-dehydrogenase (nadp+) deficiency
Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls.
Thecoma
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
Tics
Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells.
Uterine Cervical Neoplasms
Estrogen formation in endometrial and cervix cancer cell lines: Involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12).
Uterine Cervical Neoplasms
Increased 17ß-hydroxysteroid dehydrogenase type 1 levels in primary cervical cancer.
Uterine Diseases
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis.
Uterine Diseases
Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice.
Vaccinia
Deletion of fowlpox virus homologues of vaccinia virus genes between the 3 beta-hydroxysteroid dehydrogenase (A44L) and DNA ligase (A50R) genes.
Vaccinia
Expansion of the mammalian 3 beta-hydroxysteroid dehydrogenase/plant dihydroflavonol reductase superfamily to include a bacterial cholesterol dehydrogenase, a bacterial UDP-galactose-4-epimerase, and open reading frames in vaccinia virus and fish lymphocystis disease virus.
Vaccinia
Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus.
Varicose Veins
Elevated sex steroid hormones in great saphenous veins in men.
Vitamin A Deficiency
Retinyl esters are elevated in progeny of retinol dehydrogenase 11 deficient dams.
Wilms Tumor
New frontiers on the molecular underpinnings of hypospadias according to severity.
Wilms Tumor
Starvation is more efficient than the washing technique for purification of rat Sertoli cells.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.1.1.51 3(or 17)beta-hydroxysteroid dehydrogenase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
